A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
NCT00042588 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2005-06-24
Summary
The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.
Conditions
Interventions
- DRUG
-
Recombinant Chimeric Monoclonal Antibody
Sponsors & Collaborators
-
ICOS Corporation
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-05-31
Countries
- United States
Study Locations
More Related Trials
-
Study Testing Convalescent Plasma vs Best Supportive Care
NCT04333251 ·Status: WITHDRAWN ·Phase: PHASE1
-
Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
NCT04331795 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Changes in Severe COVID-19 Pulmonary Infections
NCT04386395 ·Status: COMPLETED
-
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
NCT04500132 ·Status: COMPLETED ·Phase: PHASE2
-
Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia
NCT04334850 ·Status: COMPLETED ·Phase: NA
-
Innate Immune Response of Blood Cells in Patients With Pneumonia
NCT03231670 ·Status: COMPLETED
-
Sensitivity Evaluation of Serological Tests for Covid-19
NCT04678024 ·Status: UNKNOWN
-
Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
NCT04912895 ·Status: COMPLETED ·Phase: NA
-
Molecular Diagnosis and Prognosis of Severe Pulmonary Infection Immunosuppressed Hosts
NCT04395066 ·Status: UNKNOWN
-
mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients
NCT05290454 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection.
NCT06334185 ·Status: NOT_YET_RECRUITING
-
Correlation Between Antibiotic Resistance and Incidence of Sepsis in Community Acquired Pneumonia
NCT05606627 ·Status: UNKNOWN
-
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
NCT04407689 ·Status: TERMINATED ·Phase: PHASE2
-
Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study
NCT05612893 ·Status: UNKNOWN
-
Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19)
NCT04365166 ·Status: UNKNOWN
-
Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia
NCT04329650 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)
NCT04498325 ·Status: WITHDRAWN ·Phase: PHASE1
-
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
NCT00111397 ·Status: COMPLETED ·Phase: PHASE1
-
Immunological Characteristics of COVID-19 Patients
NCT04679428 ·Status: UNKNOWN
-
Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
NCT04453384 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia
NCT04332913 ·Status: UNKNOWN
-
Innate Immune Response During Community Acquired Pneumonia
NCT03379207 ·Status: TERMINATED
-
Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease
NCT04779359 ·Status: UNKNOWN
-
Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia
NCT04469114 ·Status: COMPLETED ·Phase: PHASE3
-
Invasive Pulmonary Aspergillosis Complicating Influenza Infection
NCT03391492 ·Status: COMPLETED